We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Formycon AG (FYB) NPV

Sell:€49.35 Buy:€49.70 Change: €0.35 (0.70%)
Market closed |  Prices as at close on 26 February 2024 | Switch to live prices |
Change: €0.35 (0.70%)
Market closed |  Prices as at close on 26 February 2024 | Switch to live prices |
Change: €0.35 (0.70%)
Market closed |  Prices as at close on 26 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

Contact details

Fraunhoferstrasse 15
+49 (89) 864667100

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€813.89 million
Shares in issue:
16.05 million
Frankfurt Stock Exchange

Key personnel

  • Olaf Stiller
    Chairman of the Supervisory Board
  • Stefan Glombitza
    Chief Executive Officer, Member of the Executive Board
  • Peter Wendeln
    Deputy Chairman of the Supervisory Board
  • Enno Spillner
    Chief Financial Officer, Member of the Executive Board
  • Andreas Seidl
    Chief Scientific Officer, Member of the Executive Board
  • Nicola Mikulcik
    Member of the Executive Board, Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.